GSK has confirmed its intention to manufacture one billion doses of pandemic vaccine adjuvant in 2021 to support the development of multiple COVID-19 vaccine collaborations. The manufacture, fill and finish of adjuvant for use in COVID-19 vaccines will take place at sites in the UK, US, Canada, and Europe.

To support this, GSK Barnard Castle approached Howorth to provide a UDAF (Unidirectional Airflow) system that would provide Grade A airflow over the storage area for sealed bags of vial stoppers, prior to introduction into the aseptic vial filling process. Due to the fast-track nature of the project, GSK issued the strict remit to Howorth that the equipment had to be installed and commissioned by the end of 2020 to enable start of process PQ during Q1 2021. We are pleased to confirm the equipment has been installed and commissioned successfully ahead of schedule!

“Due to the urgency associated with delivering COVID solutions, this project was always going to have very demanding delivery timelines. Howorth responded with urgency, completing design and construction within aggressive timelines delivering the Unidirectional Airflow unit ahead of the accelerated program, also ensuring quality of the delivered equipment and validation package. I would certainly have no hesitation using Howorth in the future for GSK projects based on the performance demonstrated on this fast-track project and quality of equipment delivered.”

Lee Ainsley, Project Engineering Manager, GSK